275 related articles for article (PubMed ID: 7594477)
1. Interference of distinct invariant chain regions with superantigen contact area and antigenic peptide binding groove of HLA-DR.
Vogt AB; Stern LJ; Amshoff C; Dobberstein B; Hämmerling GJ; Kropshofer H
J Immunol; 1995 Nov; 155(10):4757-65. PubMed ID: 7594477
[TBL] [Abstract][Full Text] [Related]
2. A recombinant single-chain human class II MHC molecule (HLA-DR1) as a covalently linked heterotrimer of alpha chain, beta chain, and antigenic peptide, with immunogenicity in vitro and reduced affinity for bacterial superantigens.
Zhu X; Bavari S; Ulrich R; Sadegh-Nasseri S; Ferrone S; McHugh L; Mage M
Eur J Immunol; 1997 Aug; 27(8):1933-41. PubMed ID: 9295029
[TBL] [Abstract][Full Text] [Related]
3. Delivery of nascent MHC class II-invariant chain complexes to lysosomal compartments and proteolysis of invariant chain by cysteine proteases precedes peptide binding in B-lymphoblastoid cells.
Morton PA; Zacheis ML; Giacoletto KS; Manning JA; Schwartz BD
J Immunol; 1995 Jan; 154(1):137-50. PubMed ID: 7995933
[TBL] [Abstract][Full Text] [Related]
4. Class II-associated invariant chain peptide-independent binding of invariant chain to class II MHC molecules.
Thayer WP; Ignatowicz L; Weber DA; Jensen PE
J Immunol; 1999 Feb; 162(3):1502-9. PubMed ID: 9973407
[TBL] [Abstract][Full Text] [Related]
5. Editing of the HLA-DR-peptide repertoire by HLA-DM.
Kropshofer H; Vogt AB; Moldenhauer G; Hammer J; Blum JS; Hämmerling GJ
EMBO J; 1996 Nov; 15(22):6144-54. PubMed ID: 8947036
[TBL] [Abstract][Full Text] [Related]
6. The crystal structure of staphylococcal enterotoxin H: implications for binding properties to MHC class II and TcR molecules.
Hâkansson M; Petersson K; Nilsson H; Forsberg G; Björk P; Antonsson P; Svensson LA
J Mol Biol; 2000 Sep; 302(3):527-37. PubMed ID: 10986116
[TBL] [Abstract][Full Text] [Related]
7. Variation in HLA-DM expression influences conversion of MHC class II alpha beta:class II-associated invariant chain peptide complexes to mature peptide-bound class II alpha beta dimers in a normal B cell line.
Ramachandra L; Kovats S; Eastman S; Rudensky AY
J Immunol; 1996 Mar; 156(6):2196 - 2204. PubMed ID: 8690909
[TBL] [Abstract][Full Text] [Related]
8. Structural features of the invariant chain fragment CLIP controlling rapid release from HLA-DR molecules and inhibition of peptide binding.
Kropshofer H; Vogt AB; Hämmerling GJ
Proc Natl Acad Sci U S A; 1995 Aug; 92(18):8313-7. PubMed ID: 7667286
[TBL] [Abstract][Full Text] [Related]
9. Multiple binding sites on the superantigen, staphylococcal enterotoxin B, imparts versatility in binding to MHC class II molecules.
Soos JM; Johnson HM
Biochem Biophys Res Commun; 1994 Jun; 201(2):596-602. PubMed ID: 8002991
[TBL] [Abstract][Full Text] [Related]
10. Invariant chain can bind MHC class II at a site other than the peptide binding groove.
Wilson NA; Wolf P; Ploegh H; Ignatowicz L; Kappler J; Marrack P
J Immunol; 1998 Nov; 161(9):4777-84. PubMed ID: 9794409
[TBL] [Abstract][Full Text] [Related]
11. Identification from a phage display library of peptides that bind to toxic shock syndrome toxin-1 and that inhibit its binding to major histocompatibility complex (MHC) class II molecules.
Sato A; Ida N; Fukuyama M; Miwa K; Kazami J; Nakamura H
Biochemistry; 1996 Aug; 35(32):10441-7. PubMed ID: 8756700
[TBL] [Abstract][Full Text] [Related]
12. Interaction of MHC class II molecules with the invariant chain: role of the invariant chain (81-90) region.
Stumptner P; Benaroch P
EMBO J; 1997 Oct; 16(19):5807-18. PubMed ID: 9312039
[TBL] [Abstract][Full Text] [Related]
13. Identification of a sequence that mediates promiscuous binding of invariant chain to MHC class II allotypes.
Siebenkotten IM; Carstens C; Koch N
J Immunol; 1998 Apr; 160(7):3355-62. PubMed ID: 9531295
[TBL] [Abstract][Full Text] [Related]
14. Invariant chain association with MHC class I: preference for HLA class I/beta 2-microglobulin heterodimers, specificity, and influence of the MHC peptide-binding groove.
Vigna JL; Smith KD; Lutz CT
J Immunol; 1996 Nov; 157(10):4503-10. PubMed ID: 8906828
[TBL] [Abstract][Full Text] [Related]
15. Identification of binding domains on the superantigen, toxic shock syndrome-1, for class II MHC molecules.
Soos JM; Russell JK; Jarpe MA; Pontzer CH; Johnson HM
Biochem Biophys Res Commun; 1993 Mar; 191(3):1211-7. PubMed ID: 8466498
[TBL] [Abstract][Full Text] [Related]
16. Invariant chain prevents the HLA-DR-restricted presentation of a cytosolic peptide.
Long EO; LaVaute T; Pinet V; Jaraquemada D
J Immunol; 1994 Aug; 153(4):1487-94. PubMed ID: 8046228
[TBL] [Abstract][Full Text] [Related]
17. Diminished class II-associated Ii peptide binding to the juvenile dermatomyositis HLA-DQ alpha 1*0501/DQ beta 1*0301 molecule.
Reed AM; Collins EJ; Shock LP; Klapper DG; Frelinger JA
J Immunol; 1997 Dec; 159(12):6260-5. PubMed ID: 9550430
[TBL] [Abstract][Full Text] [Related]
18. Assembly and transport properties of invariant chain trimers and HLA-DR-invariant chain complexes.
Lamb CA; Cresswell P
J Immunol; 1992 Jun; 148(11):3478-82. PubMed ID: 1588042
[TBL] [Abstract][Full Text] [Related]
19. Characterization of endogenous peptides bound to purified HLA-DR molecules and their absence from invariant chain-associated alpha beta dimers.
Newcomb JR; Cresswell P
J Immunol; 1993 Jan; 150(2):499-507. PubMed ID: 8419482
[TBL] [Abstract][Full Text] [Related]
20. HLA-DO increases bacterial superantigen binding to human MHC molecules by inhibiting dissociation of class II-associated invariant chain peptides.
Pezeshki AM; Azar GA; Mourad W; Routy JP; Boulassel MR; Denzin LK; Thibodeau J
Hum Immunol; 2013 Oct; 74(10):1280-7. PubMed ID: 23756162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
